Skip to content

Medpace Holdings, Inc.

MEDP· NasdaqCore metricsCIK 1668397

Commercial physical & biological research16 peers

Last sale
Nov 12, 2026 · -1.28%
Market cap
$18.36B
27.97M shares
Filings
932
$716.00M
Q3 2026+20.0% FY25 yoy
$137.46M
Q3 2026+11.6% FY25 yoy
$165.54M
Q3 2026+19.7% FY25 yoy
$479.51M
Q3 2026derived+19.2% FY25 yoy
$4.84
Q3 2026+21.0% FY25 yoy
$705.32M
Q3 2026−25.8% FY25 yoy
$18.36B
35.5×
6.5×
31.4×
3.64%
—

Twelve months to Sep 30, 2026 · derived

Price

$656.43+8.98%+$54.09past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$2.53BFY 2025
$2.53B0FY 2015FY 2020FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$2,530,234,000reported
FY 20242024-12-31$2,109,054,000reported
FY 20232023-12-31$1,885,842,000reported
FY 20222022-12-31$1,459,996,000reported
FY 20212021-12-31$1,142,377,000reported
FY 20202020-12-31$925,925,000reported
FY 20192019-12-31$860,969,000reported
FY 20182018-12-31$704,589,000reported
FY 20172017-12-31$436,152,000reported
FY 20162016-12-31$421,582,000reported
FY 20152015-12-31$359,059,000reported

Capital returns

Dividends and buybacks · FY2016 to FY2025
Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2025—$917.39M$917.39M—28.38M sh−6.8%134.5%
FY2024—$169.87M$169.87M—30.47M sh−1.0%29.7%
FY2023—$144.02M$144.02M—30.76M sh−0.9%36.3%
FY2022—$847.85M$847.85M—31.05M sh−11.9%241.4%
FY2021—$62.10M$62.10M—35.23M sh−1.4%26.4%

Segments

Long-lived assets by Geography, FY2019 to FY2025FY2019United States · FY2019 · $25.60MEurope, Belgium · FY2019 · $10.05MAsia-Pacific · FY2019 · $5.67MEurope, Other · FY2019 · $5.73MOther · FY2019 · $245.00KFY2020United States · FY2020 · $58.12MEurope, Belgium · FY2020 · $12.02MAsia-Pacific · FY2020 · $6.57MEurope, Other · FY2020 · $7.96MOther · FY2020 · $6.91MFY2021United States · FY2021 · $64.83MEurope, Belgium · FY2021 · $12.34MEurope, Other · FY2021 · $8.41MOther · FY2021 · $7.57MFY2022United States · FY2022 · $81.22MEurope, Belgium · FY2022 · $11.78MAsia-Pacific · FY2022 · $6.22MEurope, Other · FY2022 · $9.29MOther · FY2022 · $1.34MFY2023United States · FY2023 · $77.85MEurope, Belgium · FY2023 · $18.19MAsia-Pacific · FY2023 · $14.47MEurope, Other · FY2023 · $8.77MOther · FY2023 · $1.31MFY2024United States · FY2024 · $80.69MEurope, Belgium · FY2024 · $18.56MAsia-Pacific · FY2024 · $14.55MEurope, Other · FY2024 · $7.46MOther · FY2024 · $2.36MFY2025United States · FY2025 · $83.90MEurope, Belgium · FY2025 · $23.00MAsia-Pacific · FY2025 · $14.91MEurope, Other · FY2025 · $6.82MOther · FY2025 · $2.43M
LineFY2025ShareChange
United States$83.90M64%+4.0%
Europe, Belgium$23.00M18%+23.9%
Asia-Pacific$14.91M11%+2.5%
Europe, Other$6.82M5.2%−8.5%
Other$2.43M1.9%+2.9%
Total$131.06M

From the 10-K filed Feb 10, 2026MEDP

Commercial physical & biological research

Medpace Holdings, Inc. is the 5th largest of the 17 covered companies the SEC files under this code, by revenue. SIC 8731

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Medpace Holdings, Inc. · CIK 1668397 · Engraved from SEC EDGAR